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Background/aim: In the present study, we aimed to investigate the relationship between NT-proBNP and SYNTAX score, which is a
measure of the complexity of coronary artery disease.
Materials and methods: We enrolled 405 consecutive patients with myocardial infarction who underwent coronary angiographic
examination. Patients were divided into 3 groups according to their SYNTAX scores. Those with SYNTAX score ≤22 were included in
the low SYNTAX score group (LSTX), those with a score of 23–32 were included in the intermediate SYNTAX score group (ISTX), and
those with a score of ≥33 were included in the high SYNTAX score group (HSTX).
Results: NT-proBNP levels were found to be significantly higher in the HSTX group compared to the other groups (P < 0.001) and in
the ISTX group compared to the LSTX group (P < 0.001). The NT-proBNP levels demonstrated an increase from low SYNTAX score to
high SYNTAX score tertiles.
Conclusions: NT-ProBNP levels in patients with myocardial infarction on admission were independently associated with extent,
severity, and complexity of coronary atherosclerosis as assessed by SYNTAX score.
Key words: Myocardial infarction, NT-proBNP, severity of coronary artery disease

1. Introduction
Coronary artery disease (CAD) remains the most important
cause of death in the world. Acute coronary syndromes (ACS)
that involve ST elevation myocardial infarction (STEMI),
non-ST elevation myocardial infarction (NSTEMI),
and unstable angina pectoris (UAP) are important lifethreatening disease groups. Various scoring systems are
used for risk identification in ACS. One of these systems is
the SYNTAX (STX) score, used to estimate the extent and
complexity of CAD [1] and consequently early and late
results [2]. This scoring system divides patients into different
risk groups according to angiographic characteristics and
provides foresight into the success of revascularization
and early/late prognosis according to risk groups [3–5].
Previous studies have shown that high levels of hs-troponin
[6], low-density lipoprotein (LDL), ApoB [7], procalcitonin
[8], uric acid [9], and high-sensitivity C-reactive protein
(hs-CRP) [10] are associated with high STX scores.
N-terminal probrain natriuretic peptide (NT-proBNP) is a
biomarker released from the myocardium due to increased
myocardial stress and used for diagnosis of heart failure
[11]. It has been shown that NT-proBNP was secreted by
ischemic myocardium [12] and high levels of NT-proBNP

are associated with poor prognosis in myocardial infarction
(MI) [13,14] in patients who underwent percutaneous
coronary interventions [15]. Thus, high NT-proBNP levels
in patients with MI can identify patients who are at a higher
risk for adverse cardiovascular events and death. However, it
is not clear which mechanism plays a role in the association
of high NT-proBNP levels and increased mortality and poor
prognosis. The extent and severity of CAD could represent a
mechanism to explain this relation.
In the present study, we aimed to investigate the
relationship between NT-proBNP and SYNTAX score,
which is a measure of the prevalence and complexity of
CAD in patients with MI.
2. Materials and methods
2.1. Ethics statement
This study was approved by an institutional ethical
review committee of the Faculty of Medicine, Kırıkkale
University, and the reporting of the study conforms to the
STROBE statement, along with references to the STROBE
statement and the broader EQUATOR guidelines [16]. The
study was conducted according to the principles expressed
in the Declaration of Helsinki.
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2.2. Study population
Four hundred and five consecutive patients with MI who
underwent coronary angiographic examination between
January 2016 and June 2018 were enrolled in the study
retrospectively. Patients were classified into two groups
according to electrocardiographic findings as NSTEMI or
STEMI.
2.3. Diagnostic criteria
Patients with typical chest pain for at least 20 min and
elevated troponin I values with ≥1 mm ST segment
elevation in 2 adjacent leads (>0.2 mV in leads V1, V2,
or V3), or a new left bundle branch block in ECG were
defined as having STEMI. Patients with typical chest pain
for at least 20 min and elevated troponin I values with or
without new horizontal ≥0.05 mV ST depression in at least
2 adjacent leads were accepted as having NSTEMI.
2.4. Exclusion criteria
Patients who had no NT-proBNP measurements or had
normal troponin I values were not included in the study
population. Patients with prior CABG, active infection,
chronic inflammatory disease, hepatic and renal disease,
known congestive heart failure or cancer, severe valve
disease, preprocedural resuscitation, or systolic and
diastolic heart failure with Killip class III–IV were
excluded. Fifty-four patients were excluded from the study
based on the exclusion criteria.
2.5. Laboratory assays and imaging modalities
Blood samples were collected at admission for NT-proBNP
and other routine blood tests. NT-proBNP measurements
were made with a COBAS 411 Roche device. Transthoracic
echocardiography was performed for all patients within
24 h after hospitalization. Coronary angiography was
performed with a General Electric Optima device.
2.6. STX classifications
Coronary artery lesions were evaluated by two invasive
cardiologists. STX scores were determined for each
coronary lesion with stenosis of >50%, in vessels >1.5 mm,
and calculated using the SYNTAX score website (www.
syntaxscore.com). Patients were divided into 3 groups
according to their SYNTAX scores. Those with a SYNTAX
score of ≤22 were included in the low SYNTAX score group
(LSTX), those with a score of 23–32 were included in the
intermediate SYNTAX score group (ISTX), and those with
a score of ≥33 were included in the high SYNTAX score
group (HSTX).
2.7. Statistical analysis
All analyses were performed using SPSS 21.0 for
Windows (IBM Corp., Armonk, NY, USA). Continuous
variables were expressed as mean ± standard deviation
for parametric variables and as median and interquartile
range for nonparametric variables. Categorical variables
were represented as numbers and percentages. The

Kolmogorov–Smirnov test was used to assess the normality
of the distribution; data were analyzed for homogeneity
using Levene tests. Comparisons of parametric values
between groups were performed by the one-way ANOVA
test and nonparametric values were performed by the
Kruskal–Wallis test. Categorical variables were compared
using the chi-square test. Receiver operating characteristic
(ROC) curve analysis was carried out in order to determine
the best cut-off value of NT-proBNP; the sensitivity and
specificity at that point were obtained. The area under the
curve (AUC) was used to determine how NT-proBNP
can distinguish between HSTX and other STX groups.
Univariate logistic regression analysis was used to identify
independent predictors of HSTX. After univariate analysis,
significantly obtained variables were used in multivariate
logistic regression analysis. Statistical significance was
accepted at P < 0.05.
3. Results
Four hundred and five consecutive patients with MI were
included in the study. The baseline characteristics of the
study population classified according to SYNTAX score
tertiles are shown in Table 1. Mean age was significantly
lower in the LSTX group than in the other groups ( P1 <
0.002, P2 < 0.001). Incidence of diabetes mellitus was found
to be higher in the HSTX group than in the other groups (P1
= 0.17, P2 = 0.001). Family history and smoking was higher
in the LSTX group than in the other groups (P1 = 0.19, P2 =
0.039 and P1 = 0.039, P2 = 0.062, respectively). The ejection
fraction was found to be higher in the LSTX group than
the other groups (P1 < 0.001, P2 < 0.001). There was no
significant difference in the sex, presence of hypertension,
hyperlipidemia, prior stroke, blood pressure, or subgroup
of MI. Laboratory measurements of the patients stratified
into STX tertiles are shown in Table 2. Hemoglobin values
were significantly lower in the ISTX group than in the
LSTX group (P1 = 0.041), and creatinine clearance levels
were significantly lower in the HSTX group than the LSTX
group and in the ISTX group than the LSTX group (P1 =
0.020, P2 < 0.001). Serum glucose (P1 = 0.10, P2 = 0.003),
HbA1c (P1 = 0.31, P2= 0.048), and troponin levels (P1 <
0.001, P2 = 0.049) were significantly lower in the LSTX
group than in the other groups. We found that there was
a positive correlation between NT-proBNP and troponin
I when we performed Spearman correlation analysis (P
= 0.001, r = 0.292). NT-proBNP levels were found to be
significantly higher in the HSTX group than in the LSTX
group (P < 0.001) and in the ISTX group higher than in the
LSTX group (P < 0.001) (Figure 1). The NT-proBNP levels
demonstrated an increase from LSTX to HSTX tertiles
(Table 2).
When evaluated in terms of culprit artery, we found
that the mean NT-proBNP values were 2673 pg/mL in left
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Table 1. Baseline characteristics of patients classified into SYNTAX score groups.
Variables

LSTX
(n = 261)

ISTX
(n = 107)

HSTX
(n = 37)

P1 value

P2 value

Age, years (mean ± SD)

60 ± 12

65 ± 13

70 ± 11

0.002

<0.001

Male sex, n (%)

184 (70.2)

62 (57.9)

23 (63.9)

0.081

0.98

Hypertension, n (%)

113 (44.7)

55 (52.9)

21 (61.8)

0.37

0.13

Diabetes mellitus, n (%)

75 (29.5)

41 (39.4)

21 (61.8)

0.17

<0.001

Hyperlipidemia, n (%)

75 (29.6)

31 (29.8)

6 (17.6)

0.99

0.40

Current smoker, n (%)

125 (48.6)

36 (34.0)

10 (27.8)

0.039

0.062

Family history, n (%)

51 (20.2)

13 (12.5)

1 (2.9)

0.19

0.039

Prior stroke, n (%)

4 (1.6)

3 (2.8)

2 (5.6)

0.70

0.83

Left ventricle EF (%)

48 ± 9

41 ± 9

41 ± 10

< 0.001

<0.001

Systolic BP, mmHg

132 ± 26

126 ± 26

125 ± 25

0.15

0.21

Diastolic BP, mmHg

79 ± 14

77 ± 16

74 ± 12

0.42

0.22

STEMI, n (%)

165 (63.0)

71 (66.4)

18 (50.0)

Non-STEMI, n (%)

97 (37.0)

36 (33.6)

18 (50)

EF, Ejection fraction; BP, blood pressure; STEMI, ST-segment elevation myocardial infarction. P1, Comparison
between LSTX and ISTX; P2, comparison between LSTX and HSTX.
Table 2. Laboratory measurements of patients classified into SYNTAX score groups.
Variables

LSTX

ISTX

HSTX

P1 value

P2 value

Hemoglobin (g/dL)

14.10 ± 1.8

13.60 ± 2.0

13.40 ± 1.60

0.041

0.34

WBC (103/µL)

10.6 ± 3.2

11.7 ± 3.8

9.9 ± 3.9

0.030

0.31

3

Platelet (10 /µL)

239 ± 71

240 ± 65

232 ± 92

0.98

0.31

Serum glucose (mg/dL)

145 ± 74

162 ± 84

191 ± 93

0.10

0.003

HbA1c (%)

6.8 ± 1.9

7.2 ± 2.1

7.7 ± 2.0

0.31

0.048

eGFR (mL/min)

73 ± 20

67 ± 20

56 ± 15

0.020

<0.001

Total cholesterol (mg/dL)

197 ± 53

193 ± 55

185 ± 47

0.72

0.33

Triglyceride (mg/dL)

135 (91–214)

133 (89–199)

137 (111–223)

0.89

0.43

LDL cholesterol (mg/dL)

125.87 ± 41.12

121.65 ± 49.27

111.53 ± 33.50

0.70

0.13

HDL cholesterol (mg/dL)

40.34 ± 9.17

41.44 ± 10.77

42.42 ± 8.32

0.92

0.85

Peak troponin T (ng/L)

1840 (302–2307)

3262 (603–6102)

3315 (515–5010)

<0.001

0.049

Hs-CRP (mg/dL)

6.8 ± 3.9

7.5 ± 3.7

8.0 ± 3.4

0.38

0.59

NT-ProBNP (pg/mL)

607 (160–1899)

1369 (583–3627)

2760 (779–6865)

<0.001

<0.001

WBC, White blood cell count; HbA1c, glycated hemoglobin; eGFR, glomerular filtration rate; LDL, low-density lipoprotein; HDL, highdensity lipoprotein; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal probrain natriuretic peptide. P1, Comparison
between LSTX and ISTX; P2, comparison between LSTX and HSTX.

anterior descending artery (LAD) lesions, 2408 pg/mL in
circumflex artery (CX) lesions, and 1664 pg/mL in right
coronary artery (RCA) lesions. There was a statistically
significant difference in NT-proBNP values between LAD
and RCA lesions (P = 0.018). However, no significant
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difference was found between LAD-CX and CX-RCA
lesions (P = 0.564 and P = 0.149, respectively).
The presence of multivessel disease and chronic total
occlusion, as well as type of treatment between groups,
are presented in Table 3. Patients with HSTX had a
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significantly higher rate of multivessel disease and chronic
total occlusion compared to ISTX and LSTX (P < 0.001
and P < 0.001, respectively). The ratio of percutaneous
coronary intervention was higher in patients with LSTX
and the ratio of CABG surgery was higher in patients with
HSTX.
The optimal value of the cut-off point for NT-proBNP
to predict HSTX was 1719 pg/mL (sensitivity 70%,
specificity 63%) (Figure 2). The patients were divided into
two groups based on the cut-off point of 1719 pg/mL;
mean STX score was significantly higher in the patients
who had NT-proBNP levels above this cut-off value
(Figure 3).
Univariate logistic regression analyses were used to
determine independent predictors of HSTX (variables:

age, diabetes mellitus, smoking, family history, LVEF,
WBC, glucose, creatinine, and NT-proBNP [>1719 pg/
mL]). Multivariate logistic regression analyses were
performed for significantly obtained variables (age,
diabetes mellitus, LVEF, glucose, and NT-proBNP [>1719
pg/mL]). After multivariate logistic regression analysis
we found that the strongest predictors of HSTX were
increased serum NT-proBNP (>1719 pg/mL) (OR: 2.982,
95% CI: 1.328–6.694, P = 0.008), age (OR: 1.041, 95% CI:
1.012–1.073, P = 0.004), and serum glucose level (OR:
1.004, 95% CI: 1.001–1.008, P = 0.024) (Table 4).
4. Discussion
In the present study we found that high NT-proBNP levels
were associated with high SYNTAX scores in patients with

Figure 1. Comparison of N-terminal probrain natriuretic peptide (NT-proBNP) levels
among SYNTAX score (STX) groups.
Table 3. Angiographic assessment and therapy choice by SYNTAX score groups.
LSTX

ISTX

HSTX

P-value

Multivessel disease, n (%)

130 (51.0)

84 (82.4)

33 (100)

<0.001

Chronic total occlusion, n (%)

27 (10.6)

35 (34.3)

22 (66.7)

<0.001

Type of procedure, n (%)
Medical
PCI
CABG

3 (1.2)
241 (94.5)
11 (4.3)

2 (1.9)
80 (77.7)
21 (20.4)

0 (0.0)
15 (45.5)
18 (54.5)

<0.001

PCI, Percutaneous coronary intervention; CABG, coronary artery bypass grafting.
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Figure 2. The receiver-operating characteristic (ROC) curve analysis for N-terminal
probrain natriuretic peptide (NT-proBNP) levels in predicting patients with HSTX.
Area under the curve (AUC): 0.699 (0.606–0.791).

Figure 3. Patients were divided into two groups based on the cut-off point of 1719
pg/mL; mean STX score was significantly higher in the patients who had NT-proBNP
levels above this cut-off value.

STEMI and NSTEMI. NT-proBNP levels were found to be
significantly higher in the HSTX group compared to the
other groups, and in the ISTX group compared to LSTX
group. The NT-proBNP levels demonstrated an increase
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from low STX score to high STX score tertiles. Thus, in
the present study, we suggest that the NT-proBNP level is
related with severity and complexity of CAD in patients
with acute MI.
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Table 4. Predictors of high SYNTAX score (>33) in univariate and multivariate analyses.
Univariate OR (95% CI)

P-value

Multivariate OR (95% CI)

P-value

Age

1.055 (1.025–1.087)

<0.001

1.041 (1.012–1.073)

0.004

Diabetes mellitus

3.553 (1.679–7.517)

0.001

1.840 (0.884–5.032)

0.056

Smoking

0.479 (0.216–1.065)

0.071

Family history

0.147 (0.020–1.098)

0.062

LVEF

0.942 (0.906–0.979)

0.003

0.961 (0.921–1.003)

0.070

WBC

0.888 (0.786–1.002)

0.055

Glucose

1.005 (1.002–1.009)

0.004

1.004 (1.001–1.008)

0.024

Creatinine

2.853 (0.945–8.610)

0.063

NT-proBNP >1719 pg/mL

3.643 (1.722–7.708)

0.001

2.982 (1.328–6.694)

0.008

LVEF, Left ventricle ejection fraction; WBC, white blood cell count; NT-proBNP, N-terminal probrain natriuretic
peptide.

It has been shown that cardiomyocyte tension leads
to BNP secretion [17,18]. BNP secretion increases when
myocardial wall tension increases [19]. Elevated BNP
levels were observed in systolic and diastolic heart failure,
which were the cause of increased end-diastolic pressure
[20–22]. Increased NT-proBNP is associated with severity
of ischemia [23,24] and poor prognosis in ACS [25,26].
The SYNTAX score is used to detect the extent and
complexity of CAD [1,27] and to predict prognosis in
patients with CAD [3–5]. Akgün et al. demonstrated that
STX is an independent predictor of both in-hospital and
long-term mortality and major adverse cardiac events in
patients with STEMI undergoing primary percutaneous
coronary intervention (PCI) [28]. In the angiographic
substudy of the ACUITY study of 2627 patients with
NSTEMI undergoing PCI, STX was an independent
predictor of 1-year rates of mortality, cardiac death, MI,
and target vessel revascularization [29]. Valgimigli et
al. demonstrated that STX predicts clinical outcome in
patients with three vessel lumen obstruction undergoing
PCI [30].
Previous studies have shown a correlation between STX
and some biochemical parameters such as hs-troponin,
LDL, ApoB, procalcitonin, and hs-CRP [6–8,10]. In the
present study, we found that high NT-proBNP levels were
associated with HSTX in patients with acute MI. The most
likely cause of this result is increased wall stress caused by
MI. Early studies showed that acute ischaemia increases
left ventricular end diastolic pressure [31] and the main
trigger mechanism for BNP secretion is cardiomyocyte
tension [32]. Ischemia itself, on the other hand, leads to
BNP release [33]. Another mechanism may be disruption
of cell wall integrity during ischemia that leads to BNP
release independently of hemodynamic effects [34].
Neurohumoral factors secreted during MI and tachycardia

also lead to BNP release [35,36]. Thus, these mechanisms
could contribute to NT-BNP release. Patients with high
STX scores have greater ischemic burden, more wall
tension elevation, and more necrosis; it is to be expected
that these patients have higher NT-proBNP levels.
Early risk stratification is very important in patients
presenting with suspected acute myocardial infarction
due to major clinical relevance for identifying individuals
at risk of death and guiding further diagnostics and/or
therapeutic pathways. Different risk stratification scores
are used in clinical practice, such as the TIMI score,
GRACE score, log EUROSCORE, AMIS score, and others.
These scoring systems use some clinical and laboratory
parameters. We suggest that NT-proBNP could be used
as a laboratory parameter for early risk stratification in
patients with myocardial infarction.
There was a strong relationship between NT-proBNP
levels and STX tertiles in this study. NT-proBNP levels
gradually rose from the LSTX to the HSTX group. We
found that NT-proBNP (>1719 pg/mL), age, diabetes
mellitus, LVEF, and glucose were independent predictors
of HSTX and increased serum levels of NT-proBNP were a
strong predictor of HSTX in patients with MI. Multivessel
disease, chronic total occlusion, and CABG were
significantly higher in the HSTX group than in the other
groups. Patients who have greater ischemic burden have
higher NT-ProBNP levels. The relationship between NTproBNP and poor prognosis is not completely explained.
We suggest that high STX scores may explain this relation.
In conclusion, NT-ProBNP levels in patients with
STEMI and NSTEMI on admission were independently
associated with the extent, severity, and complexity of
coronary atherosclerosis as assessed by STX score. NTproBNP levels can be used for early risk classification in
clinical practice in patients with MI.

1371

SARAK and KARADENİZ / Turk J Med Sci
This study has several limitations. First, STX was
calculated from coronary angiographic findings by visual
interpretation. Second, the concentration of NT-proBNP

was only measured at admission and without correction
for potential variability.
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